An Exploratory Study of the Biological and Clinical Activity of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2014
At a glance
- Drugs Sunitinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Breast cancer
- Focus Pharmacodynamics
- 11 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Dec 2012 Planned End Date changed from 1 Jan 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 23 Nov 2011 Planned End Date changed from 1 Sep 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.